SCHEMBL25751670

SCHEMBL25751670

CC(C)(C)N=C1N(c2ccccc2)CCN1c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
LMNA P02545 1/20 0.36
CHRNA7 P36544 2/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 1/20 0.35
CHRNB2 P17787 1/20 0.35
NFKB1 P19838 1/20 0.35
MAPK1 P28482 1/20 0.35
CHRNA3 P32297 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751667 0.89 SIGMAR1 (0.42) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL25753821 0.71 SIGMAR1 (0.48) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL9668729 0.69 SIGMAR1 (0.64) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL13629203 0.68 NPC1 (0.50) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL13762123 0.67 MEN1 (0.64) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL25753806 0.66 SIGMAR1 (0.42) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL17956811 0.66 SIGMAR1 (0.58) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL11174174 0.66 SIGMAR1 (1.00) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL10133974 0.66 SIGMAR1 (0.58) SIGMAR1NPC1RAB9AMEN1KMT2A
SCHEMBL610584 0.66 NPC1 (1.00) SIGMAR1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 SIGMAR1 4413/4885NPC1 4128/4885RAB9A 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.